Clinical Trial Update: Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema [Phase 2]

View source ↗

Summary

A Phase 2b dose-ranging study evaluated delgocitinib cream at 1, 3, 8, and 20 mg/g vs vehicle over 16 weeks in adults with chronic hand eczema; results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hand Eczema

Drugs mentioned

• Delgocitinib Cream (delgocitinib)

Snippet

Sponsor: LEO Pharma | Conditions: Chronic Hand Eczema | Phase 2 | Status: COMPLETED | Results posted: 2021-04-19